NTRA vs. LH, DGX, EXAS, RDNT, GH, FTRE, VCYT, CDNA, VRDN, and CSTL
Should you be buying Natera stock or one of its competitors? The main competitors of Natera include Laboratory Co. of America (LH), Quest Diagnostics (DGX), Exact Sciences (EXAS), RadNet (RDNT), Guardant Health (GH), Fortrea (FTRE), Veracyte (VCYT), CareDx (CDNA), Viridian Therapeutics (VRDN), and Castle Biosciences (CSTL). These companies are all part of the "medical laboratories" industry.
Laboratory Co. of America (NYSE:LH) and Natera (NASDAQ:NTRA) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, community ranking, risk, profitability, dividends, media sentiment and valuation.
Laboratory Co. of America received 145 more outperform votes than Natera when rated by MarketBeat users. However, 68.52% of users gave Natera an outperform vote while only 64.18% of users gave Laboratory Co. of America an outperform vote.
Laboratory Co. of America has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Natera has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
95.9% of Laboratory Co. of America shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 0.9% of Laboratory Co. of America shares are owned by insiders. Comparatively, 7.6% of Natera shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Laboratory Co. of America has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.
Laboratory Co. of America currently has a consensus price target of $241.86, indicating a potential upside of 24.09%. Natera has a consensus price target of $98.47, indicating a potential downside of 7.57%. Given Natera's higher probable upside, equities research analysts clearly believe Laboratory Co. of America is more favorable than Natera.
Laboratory Co. of America has a net margin of 3.52% compared to Laboratory Co. of America's net margin of -30.24%. Natera's return on equity of 14.68% beat Laboratory Co. of America's return on equity.
In the previous week, Natera had 8 more articles in the media than Laboratory Co. of America. MarketBeat recorded 18 mentions for Natera and 10 mentions for Laboratory Co. of America. Laboratory Co. of America's average media sentiment score of 0.66 beat Natera's score of 0.63 indicating that Natera is being referred to more favorably in the news media.
Summary
Laboratory Co. of America and Natera tied by winning 9 of the 18 factors compared between the two stocks.
Get Natera News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
